Does PTCY increase the risk of infections?

IF 6.9 2区医学 Q1 HEMATOLOGY Blood Reviews Pub Date : 2023-11-01 DOI:10.1016/j.blre.2023.101092

Malgorzata Mikulska , Claudia Bartalucci , Anna Maria Raiola , Chiara Oltolini

{"title":"Does PTCY increase the risk of infections?","authors":"Malgorzata Mikulska , Claudia Bartalucci , Anna Maria Raiola , Chiara Oltolini","doi":"10.1016/j.blre.2023.101092","DOIUrl":null,"url":null,"abstract":"<div>PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in matched donors allowed better evaluation of infectious risk conferred separately by PTCY or donor type.PTCY increased the risk of bacterial infections, both in haploidentical and matched donors, mainly pre-engraftment bacteremias. Bacterial infections, particularly due to multidrug-resistant Gram-negatives, were main causes of infection-related deaths.Higher rates of CMV and other viral infections were reported, mainly in haploHSCT. The role of donor might be more important than the role of PTCY. PTCY increased the risk of BK virus associated hemorrhagic cystitis, and seemed associated with higher risk of respiratory viral infections.Fungal infections were frequent in haploHSCT PCTY cohorts without mold active prophylaxis, but the exact role of PTCY needs to be established.Infections appear to be increased in patients receiving PTCY, although the exact role of GvHD prophylaxis and donor type can only be assessed in prospective trials.</div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"62 ","pages":"Article 101092"},"PeriodicalIF":6.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X2300053X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in matched donors allowed better evaluation of infectious risk conferred separately by PTCY or donor type.

PTCY increased the risk of bacterial infections, both in haploidentical and matched donors, mainly pre-engraftment bacteremias. Bacterial infections, particularly due to multidrug-resistant Gram-negatives, were main causes of infection-related deaths.

Higher rates of CMV and other viral infections were reported, mainly in haploHSCT. The role of donor might be more important than the role of PTCY. PTCY increased the risk of BK virus associated hemorrhagic cystitis, and seemed associated with higher risk of respiratory viral infections.

Fungal infections were frequent in haploHSCT PCTY cohorts without mold active prophylaxis, but the exact role of PTCY needs to be established.

Infections appear to be increased in patients receiving PTCY, although the exact role of GvHD prophylaxis and donor type can only be assessed in prospective trials.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PTCY会增加感染的风险吗?

PTCY主要用于单倍体移植(haploHSCT)，但在匹配供体中使用PTCY可以更好地评估PTCY或供体类型分别赋予的感染风险。PTCY增加了细菌感染的风险，在单倍体相同和匹配的供体中，主要是移植前的细菌血症。细菌感染，特别是多药耐药革兰氏阴性菌引起的细菌感染，是导致感染相关死亡的主要原因。据报道，CMV和其他病毒感染率较高，主要发生在单倍造血干细胞移植中。捐助者的作用可能比PTCY的作用更重要。PTCY增加了BK病毒相关出血性膀胱炎的风险，并且似乎与呼吸道病毒感染的高风险相关。真菌感染在没有霉菌积极预防的单倍hsct PCTY队列中很常见，但PTCY的确切作用需要确定。虽然只有在前瞻性试验中才能评估GvHD预防和供体类型的确切作用，但接受PTCY的患者感染似乎有所增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Blood Reviews 医学-血液学

CiteScore

13.80

自引率

1.40%

发文量

期刊介绍： Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.

期刊最新文献

Editorial Board Breaking down frailty: Assessing vulnerability in acute myeloid leukemia Longitudinal clinical manifestations of Fanconi anemia: A systematized review Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?